Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

KV Pharma Says it Reached Manufacturing Agreement

By Pharmaceutical Processing | March 3, 2009

ST. LOUIS (AP) — KV Pharmaceutical Co., a drugmaker that suspended its manufacturing and shipping operations and has recalled products four times since last fall, said Monday it has reached an agreement with regulators that would allow it to resume those operations if it passes inspections. KV said it agreed to have an independent third party review its manufacturing facilities to certify they meet industry standards, which are called current good manufacturing practices. After that review, the Food and Drug Administration will determine if the facilities are compliant. The FDA will treat some products, including prenatal vitamins and hematinic products — or drugs designed to elevate levels of oxygen-carrying hemoglobin in the blood — as if they were new drug candidates. KV will be allowed to resume distribution of some of those products, which were the subject of a recall in early February, unless the FDA approves new drug applications for the products. The news sent KV shares up 41 cents, or 60.3 percent, to $1.09 in afternoon trading. After manufacturing resumes, KV will be required to submit to additional independent inspections at least every six months for the next two years, and annual inspections for the following three years, according to the U.S. Department of Justice. If KV does not comply with the agreement, termed a consent decree, or with good manufacturing practices or FDA guidelines, the FDA can order the company to cease operations, recall products, pay damages or take other corrective steps. KV recalled most of its products and ceased manufacturing and shipping in late January because the company could not certify the drugs were made under acceptable conditions. The company recalled other drugs in November and December because some tablets were accidentally oversized, which could have delivered larger-than-intended doses.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE